Cancer Clinical Trials
description
Transcript of Cancer Clinical Trials
![Page 1: Cancer Clinical Trials](https://reader033.fdocuments.us/reader033/viewer/2022051002/5681632f550346895dd3aabf/html5/thumbnails/1.jpg)
Cancer Clinical Trials
In-Depth Information
![Page 2: Cancer Clinical Trials](https://reader033.fdocuments.us/reader033/viewer/2022051002/5681632f550346895dd3aabf/html5/thumbnails/2.jpg)
2
The Drug Development and Approval Process
1. Early research and preclinical testing2. IND application filed with FDA3. Clinical trials (phases 1, 2, and 3)4. NDA filed with FDA5. FDA validates claim and approves drug
![Page 3: Cancer Clinical Trials](https://reader033.fdocuments.us/reader033/viewer/2022051002/5681632f550346895dd3aabf/html5/thumbnails/3.jpg)
3
Phases of Clinical Trials• Phase 1: 15-30 people
– What dosage is safe?– How should treatment be given?– How does treatment affect the body?
• Phase 2: Less than 100 people– Does treatment do what it is supposed to?– How does treatment affect the body?
![Page 4: Cancer Clinical Trials](https://reader033.fdocuments.us/reader033/viewer/2022051002/5681632f550346895dd3aabf/html5/thumbnails/4.jpg)
4
Phases of Clinical Trials• Phase 3: From 100 to thousands of people
– Compare new treatment with current standard• Phase 4: From hundreds to thousands of
people– Usually takes place after drug is approved– Used to further evaluate long-term safety and
effectiveness of new treatment
![Page 5: Cancer Clinical Trials](https://reader033.fdocuments.us/reader033/viewer/2022051002/5681632f550346895dd3aabf/html5/thumbnails/5.jpg)
5
Types of Clinical Trials• Treatment• Prevention• Screening and early detection• Diagnostic• Genetics• Quality-of-life / supportive care
![Page 6: Cancer Clinical Trials](https://reader033.fdocuments.us/reader033/viewer/2022051002/5681632f550346895dd3aabf/html5/thumbnails/6.jpg)
6
Treatment Trials• Test safety and effectiveness
of new agents or interventions in people with cancer
• Possible benefit:– Early access to new treatments
• Possible risk:– Occurrence of unknown side effects
![Page 7: Cancer Clinical Trials](https://reader033.fdocuments.us/reader033/viewer/2022051002/5681632f550346895dd3aabf/html5/thumbnails/7.jpg)
7
Prevention Trials• For people at risk of
developing cancer• Action studies vs. agent studies• Possible benefit:
– Early access to new interventions• Possible risk:
– Unknown side effects and effectiveness
![Page 8: Cancer Clinical Trials](https://reader033.fdocuments.us/reader033/viewer/2022051002/5681632f550346895dd3aabf/html5/thumbnails/8.jpg)
8
Screening and Early-Detection Trials• Assess new means of detecting cancer earlier in
healthy people• Possible benefit:
– Detecting disease at an earlier stage, resulting in improved outcomes
• Possible risks:– Discomfort and inconvenience– If imaging technique is studied, exposure to x-rays or radioactive
substances
![Page 9: Cancer Clinical Trials](https://reader033.fdocuments.us/reader033/viewer/2022051002/5681632f550346895dd3aabf/html5/thumbnails/9.jpg)
9
Diagnostic Trials• Develop better tools for classifying types and
phases of cancer and managing patient care• Possible benefits:
– New technology may be better and less invasive– Earlier detection of recurrences
• Possible risk:– May require people to take multiple tests
![Page 10: Cancer Clinical Trials](https://reader033.fdocuments.us/reader033/viewer/2022051002/5681632f550346895dd3aabf/html5/thumbnails/10.jpg)
10
Genetics Trials• These trials seek to:
– Determine how one’s genetic makeup can influence detection, diagnosis, prognosis, and treatment
– Broaden understanding of causes of cancer– Develop targeted treatments based on the
genetics of a tumor
![Page 11: Cancer Clinical Trials](https://reader033.fdocuments.us/reader033/viewer/2022051002/5681632f550346895dd3aabf/html5/thumbnails/11.jpg)
11
Quality-of-Life / Supportive Care Trials
• Aim to improve quality of life for patients and their families
• Possible benefit:– Early access to new treatment
• Possible risk:– May not benefit from participation
![Page 12: Cancer Clinical Trials](https://reader033.fdocuments.us/reader033/viewer/2022051002/5681632f550346895dd3aabf/html5/thumbnails/12.jpg)
12
Clinical Trial ProtocolA written, detailed action plan that:• Provides background about the trial• Specifies trial objectives• Describes trial’s design and organization• Ensures that trial procedures are
consistently carried out
![Page 13: Cancer Clinical Trials](https://reader033.fdocuments.us/reader033/viewer/2022051002/5681632f550346895dd3aabf/html5/thumbnails/13.jpg)
13
Investigational Drug UseOutside of a Clinical Trial
• Group C drugs• Treatment Investigational New Drug
application• Compassionate use program
![Page 14: Cancer Clinical Trials](https://reader033.fdocuments.us/reader033/viewer/2022051002/5681632f550346895dd3aabf/html5/thumbnails/14.jpg)
14
Clinical Trial Design• Eligibility criteria: Can range from general
(age, sex, type of cancer) to specific (prior treatment, tumor characteristics, blood cell counts, organ function); eligibility criteria also vary with trial phase– Varies with protocol and phases
• Endpoint: Measurable outcome that indicates an intervention’s effectiveness
![Page 15: Cancer Clinical Trials](https://reader033.fdocuments.us/reader033/viewer/2022051002/5681632f550346895dd3aabf/html5/thumbnails/15.jpg)
15
Clinical Trial Design• Randomization: A method used to prevent bias in
research; a computer or a table of random numbers generates treatment assignments, and participants have an equal chance to be assigned to one of two or more groups (e.g., the control group or the investigational group)
![Page 16: Cancer Clinical Trials](https://reader033.fdocuments.us/reader033/viewer/2022051002/5681632f550346895dd3aabf/html5/thumbnails/16.jpg)
16
Randomization
![Page 17: Cancer Clinical Trials](https://reader033.fdocuments.us/reader033/viewer/2022051002/5681632f550346895dd3aabf/html5/thumbnails/17.jpg)
17
Clinical Trial Design• Stratification: Categorizing subjects into
subgroups by specific characteristics– Enables researchers to look into separate
subgroups to see whether differences exist
![Page 18: Cancer Clinical Trials](https://reader033.fdocuments.us/reader033/viewer/2022051002/5681632f550346895dd3aabf/html5/thumbnails/18.jpg)
18
Stratification
![Page 19: Cancer Clinical Trials](https://reader033.fdocuments.us/reader033/viewer/2022051002/5681632f550346895dd3aabf/html5/thumbnails/19.jpg)
19
The Final Step: FDA Approval• Review of New Drug Application (NDA) or
Biologics License Application (BLA)• Labeling• Continued monitoring• Feedback
![Page 20: Cancer Clinical Trials](https://reader033.fdocuments.us/reader033/viewer/2022051002/5681632f550346895dd3aabf/html5/thumbnails/20.jpg)
20
Releasing the Results of Clinical Trials
• Peer-reviewed journals• Public announcements
– Results not made public until end of trial
![Page 21: Cancer Clinical Trials](https://reader033.fdocuments.us/reader033/viewer/2022051002/5681632f550346895dd3aabf/html5/thumbnails/21.jpg)
21
Improving Cancer Prevention, Detection, and Treatment
Once proven safe and effective in a clinical trial, an intervention may become the new standard of care
![Page 22: Cancer Clinical Trials](https://reader033.fdocuments.us/reader033/viewer/2022051002/5681632f550346895dd3aabf/html5/thumbnails/22.jpg)
22
Advancing Cancer Care• Gleevec for chronic myelogenous leukemia• Cervical cancer: improved survival rates• Breast cancer: less extensive surgery• Intron-A for melanoma• Biological therapy• Monoclonal antibodies• Cancer vaccines
![Page 23: Cancer Clinical Trials](https://reader033.fdocuments.us/reader033/viewer/2022051002/5681632f550346895dd3aabf/html5/thumbnails/23.jpg)
23
Evolution of Participant Protection• Nuremberg• Tuskegee Syphilis Study• National Commission for the Protection of
Human Subjects of Biomedical and Behavioral Research
• Belmont Report• National Research Act
![Page 24: Cancer Clinical Trials](https://reader033.fdocuments.us/reader033/viewer/2022051002/5681632f550346895dd3aabf/html5/thumbnails/24.jpg)
24
Government Oversight of Safeguards for Participants
• Office for Human Research Protections (OHRP)– The Common Rule
• FDA Regulations
![Page 25: Cancer Clinical Trials](https://reader033.fdocuments.us/reader033/viewer/2022051002/5681632f550346895dd3aabf/html5/thumbnails/25.jpg)
25
Protecting Participants Before a Trial
• Scientific review by sponsoring organization
• Institutional review board approval• Informed consent
![Page 26: Cancer Clinical Trials](https://reader033.fdocuments.us/reader033/viewer/2022051002/5681632f550346895dd3aabf/html5/thumbnails/26.jpg)
26
Protecting Participants During a Clinical Trial
• Institutional review boards (IRBs)• Data and safety monitoring boards (DSMBs)
– Minimize risks– Ensure integrity of data– Can stop study if necessary
![Page 27: Cancer Clinical Trials](https://reader033.fdocuments.us/reader033/viewer/2022051002/5681632f550346895dd3aabf/html5/thumbnails/27.jpg)
Barriers to, Benefits of, and Risks of Participation in
Clinical Trials
![Page 28: Cancer Clinical Trials](https://reader033.fdocuments.us/reader033/viewer/2022051002/5681632f550346895dd3aabf/html5/thumbnails/28.jpg)
28
Barriers to Adult Participation in Clinical Trials
Physicians and other health professionals may:• Be unaware of appropriate trials• Be unwilling to lose control of patient’s care• Believe that standard therapy is best• Believe that clinical trials are more work• Harbor concerns about the patient’s care or how the person
will react to suggestion of clinical trial participation
![Page 29: Cancer Clinical Trials](https://reader033.fdocuments.us/reader033/viewer/2022051002/5681632f550346895dd3aabf/html5/thumbnails/29.jpg)
29
Barriers to Adult Participation in Clinical Trials
Patients may:• Be unaware of clinical trials• Lack access to trials• Fear, distrust, or be suspicious of research• Have practical or personal obstacles• Face insurance or cost problems• Be unwilling to go against their physicians’ wishes
![Page 30: Cancer Clinical Trials](https://reader033.fdocuments.us/reader033/viewer/2022051002/5681632f550346895dd3aabf/html5/thumbnails/30.jpg)
30
Benefits of Participating in Clinical Trials
• Early access to new treatments• Active role in own health care• Participation in advancing medical
knowledge
![Page 31: Cancer Clinical Trials](https://reader033.fdocuments.us/reader033/viewer/2022051002/5681632f550346895dd3aabf/html5/thumbnails/31.jpg)
31
Risks of Participating in Clinical Trials
• New treatments are not always better than standard care
• Unexpected side effects• May not work for everyone• Additional cost
![Page 32: Cancer Clinical Trials](https://reader033.fdocuments.us/reader033/viewer/2022051002/5681632f550346895dd3aabf/html5/thumbnails/32.jpg)
32
NCI-Sponsored Clinical Trial Programs
• Clinical Trials Cooperative Group Program• Clinical Trials Support Unit (CTSU)• Community Clinical Oncology Program (CCOP)• Minority-Based Community Clinical Oncology
Program• Cancer Centers Program• Clinical Grants Program
![Page 33: Cancer Clinical Trials](https://reader033.fdocuments.us/reader033/viewer/2022051002/5681632f550346895dd3aabf/html5/thumbnails/33.jpg)
33
Referring Patients to Clinical Trials
Health care professionals should know:• Trial objectives• Eligibility criteria• Treatment and prevention options
![Page 34: Cancer Clinical Trials](https://reader033.fdocuments.us/reader033/viewer/2022051002/5681632f550346895dd3aabf/html5/thumbnails/34.jpg)
34
Locating NCI Clinical Trials in the Community
NCI clinical trial registry:• Nation’s most comprehensive resource
on cancer clinical trials• www.cancer.gov• 1-800-4-CANCER (1-800-422-6237)